Hydrogen sulfide: A new therapeutic target in vascular diseases

Cuilin Zhu1,2†, Qing Liu3†, Xin Li2, Ran Wei1, Tongtong Ge2, Xiufen Zheng4, Bingjin Li2, Kexiang Liu1* and Ranji Cui2*

1Department of Cardiovascular Surgery, The Second Hospital of Jilin University, Changchun, China, 2Jilin Provincial Key Laboratory on Molecular and Chemical Genetic, The Second Hospital of Jilin University, Changchun, China, 3Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan, 4Department of Surgery, Western University, London, ON, Canada

Hydrogen sulfide (H2S) is one of the most important gas transmitters. H2S modulates many physiological and pathological processes such as inflammation, oxidative stress, and cell apoptosis that play a critical role in vascular function. Recently, solid evidence show that H2S is closely associated with various vascular diseases. However, specific function of H2S remains unclear. Therefore, in this review we systemically summarized the role of H2S in vascular diseases, including hypertension, atherosclerosis, inflammation, and angiogenesis. In addition, this review also outlined a novel therapeutic perspective comprising crosstalk between H2S and smooth muscle cell function. Therefore, this review may provide new insight in H2S application clinically.

KEYWORDS
hydrogen sulfide, vascular, hypertension, angiogenesis, atherosclerosis

Introduction

Hydrogen sulfide (H2S) is recently recognized as the third gas signaling transmitter after nitric oxide (NO) and carbon monoxide (CO) despite it was once considered as toxic gas. Endogenous H2S production is mainly mediated by cystathionine-b-synthase (CBS), cystathionine-c-lyase (CSE), 3-mercaptopruvate sulfur transferase (3-MST), which are the most pre-dominant enzymes of H2S production (1–3). Exogenous administration of H2S is mainly performed with NaHS salts and H2S related compounds. Recent studies have proved H2S to be vasculoprotective by participating different cellular pathways and interfering with a variety of vascular diseases (4–7). H2S is endogenously produced by vascular cells or exogenously administered by H2S releasing donors. In the vasculature, H2S regulates the proliferation and migration of endothelial cells and vascular smooth muscle cell, regulates the apoptosis, oxidative stress and inflammation of vascular cells. Furthermore, H2S has been widely proved to regulate
many vascular diseases, including hypertension, atherosclerosis (AS) and angiogenesis (8). Although the beneficial effects of H$_2$S have widely been recognized, the mechanisms into the molecular pathways largely remained unknown. Deeper understanding of the working mechanisms will help put their way into further clinical application.

In this review, we review the recent findings about H$_2$S in vascular diseases, including hypertension, AS and angiogenesis, as well as recent working mechanisms. The role of H$_2$S will be separately discussed endogenously and exogenously here. Finally, we will discuss the possible perspectives of H$_2$S in the future.

H$_2$S in hypertension

Hypertension has been a worldwide disease, accounting for 30–40% of the whole population, posing great danger to people’s health (9, 10). It is reported that H$_2$S plays a role in blood pressure regulation. Despite emerging evidence from experimental studies targeting H$_2$S to protect against hypertension, these results need further clinical research.

Endogenous H$_2$S in hypertension

The concentration of H$_2$S in human blood has been reported within a normal range under physical conditions. However, the change of H$_2$S concentration has been reported to be reduced in high blood pressure (HBP) patients, suggesting the potential regulatory role of H$_2$S in HBP (11, 12). Several clinical studies have reported the relationship between H$_2$S and hypertension related disorders (13). Additionally, decreased H$_2$S plasmatic levels were also found in lead-induced HBP patients (14).

Furthermore, the three major generating enzymes, CSE, CBS and 3-MST were reported to be reduced in HBP patients, suggesting the endogenous synthesis of H$_2$S may participate in the pathogenesis of HBP (15). Aging is an important predisposing factor for HBP. Loss of 3-MST using a genetic mouse model recuses the mouse cardiovascular system from aging-dependent disorders, thus regulating progression of HBP (16). Innate immune and adaptive immune cells are essential in the genesis and target-organ damage of hypertension. In a recent study, Cui reported that CSE-derived H$_2$S promotes Treg differentiation and proliferation in an adenosine monophosphate activated protein kinase (AMPK) dependent pathway, which attenuates the vascular immune-inflammation, thereby preventing hypertension (17). Furthermore, DL-propargylglycine (PAG), a CSE inhibitor, was reported to increase BP in Wistar-Kyoto rats and to promote vascular remodeling, indicating the potential regulatory role of CSE in maintaining normal BP (18). Interestingly, in another study, treatment of Sprague-Dawley rats with CSE inhibitor, DL-propargylglycine (PAG) or CBS inhibitor, aminooxyacetic acid alone, did not alter the BP levels, while treatment with both inhibitors would significantly increase mean arterial pressure. This finding could partly explain the interaction of different H$_2$S producing enzymes in regulating BP (19).

As important gas transmitters, H$_2$S and NO share crosstalk in regulating pathological and physical conditions (20, 21). In hypertension, endogenous H$_2$S production regulated by CSE, inhibits endogenous endothelial NO bioavailability, therefore contributing to blood pressure control (22). Sodium nitroprusside (SNP), a NO donor, was reported to increase H$_2$S production via upregulating the CSE or CBS activity, suggesting the crosstalk between the endogenous production of two gases (23). However, the details of two gases interaction regulating blood pressure remain to be elucidated.

Taken together, endogenous H$_2$S production acts as an important physiological mediator that regulates BP homeostasis and H$_2$S deficiency will contribute to the progress of HBP.

Exogenous H$_2$S in hypertension

Apart from endogenous regulation of H$_2$S in HBP, exogenous administration of H$_2$S would regulate the process of HBP. The effects of exogenous H$_2$S donors have been widely studied in animals in different experimental settings. NaHS was the most widely used H$_2$S donor for examining the effects in treating HBP. It is reported that early treatment with sodium hydrosulfide (NaHS) (14umol/Kg/day daily intraperitoneal injection for 4 weeks) was proved to prevent the transition from pre-hypertension to hypertension in spontaneously hypertensive rats (SHRs) (24). In another study, NaHS was reported to improve endothelial dysfunction by inhibiting the NLRP3 inflammasome and oxidative stress in SHRs. However, the protective effects were abolished by knocking out Nrf2 (25). The protective effects of NaHS was also testified in an Ang-II induced HBP model, suggesting the universal effects of H$_2$S in treating HBP (26). Xiao and colleagues reported that 20-week administration of NaHS lowered the arterial pressure and increased the production of NO, enhancing eNOS phosphorylation through the activation of peroxisome proliferator-activated receptor/protein kinase B/AMP-activated protein kinase (PPAR-d/Akt/AMPK) signaling pathway (27). Administration of NaHS exerted anti hypertensive effects, promoted non-NO-mediated relaxation, and decreased oxidative stress in rats with plumbum-induced hypertension (14). Injection of NaHS was demonstrated to ameliorate soluble FMS-like tyrosine kinase 1 (sFlt1)-induced hypertension, proteinuria, and glomerular endotheliosis in rats by increasing vascular endothelial growth factor (VEGF) expression (28). NaHS administration in SHRs were proven to reduce hypertensive related inflammation, partly through
regulation of T cell subsets balance by Connexin (Cx) 40/Cx43 expressions inhibition (29). These experiment results demonstrate that NaHS dramatically suppressed the progression of HBP in different experimental settings via different mechanisms.

GY4137 was synthesized in 2018, characterized as a novel, water-soluble and long-releasing hydrogen sulfide-releasing molecule (30). GYY4137 has been reported to have anti-hypertensive effects, due to upregulating the expression of VEGFR2 (31). In another study, GYY4137 reversed blood pressure increase after Ang-II inducement, which was accompanied by upregulation of microRNA-129 (32). Exogenous GYY4137 supplementation in the paraventricular nucleus (PVN) attenuated sympathetic activity and hypertensive response, partly due to decrease of reactive oxygen species (ROS) and pro-inflammatory cytokines within the PVN in high salt-induced hypertension (33).

Apart from GYY4137 and NaHS, various H2S releasing organic compounds have been shown to exhibit protective effects in treating HBP. Allicin, which comprised a variety of sulfur-containing compounds, has been reported to exert anti-hypertensive effects in an endothelium dependent pathway (34). Sodium thiosulfate, a reversible oxidation product of H2S, has vasodilating and anti-oxidative properties in a N-ω-nitro-L-arginine (L-NNA) induced hypertension model (35). N-phenylthiourea (PTU) and N,N′-diphenylthiourea (DPTU) compounds have been investigated as potential H2S-donors, and also demonstrated typical H2S-mediated vascular properties (36). This experimental evidence advocates more extensive discovery of new H2S donors to exert more extensive application in treating HBP.

H2S does share interplay with NO and CO, regulating the pathogenesis of HBP. H2S and NO are both vasodilating mediators. H2S donors were reported to induce vasorelaxation and promote NO-donor induced vasorelaxation in rat thoracic aorta, showing the possible interaction between NO and H2S in vascular regulation (37). In L-NAME induced hypertensive rats a dysfunctional H2S pathway was revealed and exogenous H2S attenuated the elevated blood pressure in this model (38). Reducing CO levels in Brown-Norway rats increases H2S generation and prevents hypoxia-induced pulmonary edema. Increasing CO levels in SHR has been found to enhance carotid H2S generation, prevent hypersensitivity to hypoxia and control hypertension in SHR (39). H2S has also been demonstrated to exert protective effects for acute CO poisoning patients (40).

As for the mechanisms of H2S in regulating HBP, they share similar functions and several similar pathways to regulate hypertension. The possible mechanisms of H2S on vascular tone include: KATP- channel dependent relaxation, other K+ channels, PKG activation, hyperpolarization, eNOS inhibition, inhibition of cytochrome C oxidase and anti-oxidant effects (21, 41–47).

H2S not only exert anti-hypertensive effects in systematic hypertension, it also has a regulatory role in pulmonary hypertension (PHT). PHT is characterized by blood pressure increased in pulmonary artery, associated with high incidence of mortality and morbidity (48). H2S was reported to exert anti-hypertensive effects in pulmonary hypertension via vasorelaxative actions (49, 50). H2S has been proven to effectively inhibit hypoxia-induced increase in cell proliferation, migration, and oxidative stress in pulmonary artery smooth muscle cells (PASMCs) in an endoplasmic reticulum (ER) -dependent pathway, therefore exerting protective effects in PHT (51). Rashid et al. demonstrated that the relaxation response of NaHS in porcine lungs was reduced in the presence of a high concentration of K+, indicating that the mechanism of relaxation depends, in part, on K+ channel activity (52). Du group showed that H2S treatment attenuated the oxidative stress accompanied by PHT, by reducing oxidized glutathione content (53). It was also reported that endogenous sulfur dioxide pathway was down-regulated in rats with PHT, indicating the involvement of sulfur dioxide/aspartate aminotransferase 2 pathway (54).

To summarize, due to the complexity of HBP management and lack of adequate therapy, H2S is gaining increasingly attention as a potential therapeutic target. Therefore, we summarized the role of H2S in regulating hypertension in Table 1. However, the effects and mechanisms by which H2S regulates HBP are complicated and still remaining largely unknown.

**H2S and atherosclerosis**

Atherosclerosis (AS) is a long-term, chronic inflammatory disease of the vessel wall, which is widely recognized as a high risk for cardiovascular diseases (55). The progression of AS is extremely complex, involving numerous pathophysiological processes, including endothelial dysfunction, oxidative stress, inflammation, vascular smooth muscle cell proliferation and migration (56).

H2S has been reported to be a vaso-relaxant agent, which processes the property of ameliorating vascular dysfunction and mitigating the progression of AS. The potential therapeutic effects in anti-AS include maintaining endothelial cell dysfunction, inhibiting inflammation, suppressing vascular smooth muscle cell (VSMC) proliferation, migration and mitigating oxidative stress (57). However, the mechanisms of H2S to be protective against AS have not been fully elucidated and the therapeutic potential of H2S for AS treatment needs further exploration. Herein, we will review the recent findings of H2S in anti-AS from two main perspectives: endothelial cell dysfunction and inflammation.

**Endothelial cell dysfunction**

The endothelial cell represents a fundamental barrier for the maintenance of vascular homeostasis. Dysfunction in the
endothelium may lead to several cardiovascular diseases (58, 59). Therefore, protecting the vascular endothelium from damage is one of the key factors against AS and AS related disorders.

Endogenous regulation of H2S are observed to play a role in regulating AS. The concentration of H2S was found to be decreased in AS mice, indicating the potential regulatory role of H2S in AS (60). As mentioned previously, the synthesis of H2S are regulated by 3 enzymes: CBS, CSE, and 3-MST. Loss of enzyme functions may lead to endothelial dysfunction in AS. For example, CSE/H2S pathway is reported to involve in AS via the H2S/CSE-TXNIP-NLRP3-IL-18/IL-1β-nitrice oxide (NO) signaling pathway (61). Furthermore, Tian and colleagues observed that H2S deficiency derived from CSE depletion contributes to the development of endothelial dysfunction. In their study, MAPK/TXNIP (thioredoxin interacting protein signaling) is positively involved in CSE/H2S deficiency-associated endothelial dysfunction (62). CSE/H2S pathway may be protective against the formation of uremia accelerated atherosclerosis (UAAS) by affecting the expression of downstream molecule endothelial nitric oxide synthase (eNOS), which may be mediated by conventional protein kinase C (PKC) βII/Akt signaling pathway (63). Besides CSE, CBS was also observed to play a role in the process of AS. Mutations in the CBS gene are known to cause endothelial dysfunction responsible for cardiovascular and neurovascular diseases, and CBS/H2S pathway interacts with mitochondrial function and ER-mitochondrial tethering, therefore interfering with endothelial cell dysfunction-related pathologies (64). However, the role of 3-MST in maintain endothelial cell function in AS needs to be investigated. Collectively, the level of H2S and CSE/CSB/3-MST level can be considered as potential biomarkers and therapeutic targets for AS patients.

Numerous studies have demonstrated that exogenous H2S supplementation is another source contributing to the anti-AS effects. For instance, NaHS was proved to be protective against AS by upregulating angiotensin converting enzyme 2 (ACE2) expression in endothelial cells (65). Besides, H2S can reverse the endothelial dysfunction induced by AngII in HUVECs by ER stress pathway (66). Furthermore, H2S can enhance activator protein 1 (AP-1 binding) activity with the sirtuins 3 (SIRT3) promoter, thereby upregulating SIRT3 expression and ultimately reducing oxidant-provoked vascular endothelial dysfunction (67). Also Ford reported that NaHS treatment significantly reduced endothelial dysfunction and inhibited vascular

| Source  | Gene/Compound | Effects | Mechanism | Reference |
|---------|---------------|---------|-----------|-----------|
| Endogenous CSE | Inhibit inflammation | Dependent on AMPK pathway | (17) |
| CSE inhibitor | Increase hypertension | Not applicable | (18) |
| CSE inhibitor or CBS inhibitor | Increase hypertension | Not applicable | (19) |
| Exogenous NaHS | Prevent HBP | restores NO bioavailability, and blocks the RAS system in the kidney | (22) |
| | Prevent hypertension in SHR | improve endothelial dysfunction by inhibiting the NLRP3 inflammasome and oxidative stress | (25) |
| | Protective in Ang II induced HBP mice | reduces blood pressure, endothelial dysfunction and vascular oxidative stress | (26) |
| | Protective in HBP | increased the production of NO, enhancing eNOS phosphorylation via PPAR-d/Akt/AMPK pathway. | (27) |
| | anti-hypertensive in plumbum-induced hypertension | promoted non-NO-mediated relaxation, and decreased oxidative stress | (14) |
| | anti-hypertensive | Ameliorate proteinuria, and glomerular endotheilosis by increasing VEGF expression | (28) |
| | reduce hypertensive related inflammation | regulation of T cell subsets balance by Cx 40/Cx43 expressions inhibition | (29) |
| GYY4137 | anti-hypertensive | upregulating the expression of VEGF receptor 2 | (31) |
| | anti-hypertensive after Ang-II inducement | upregulating of micro RNA-129 | (32) |
| | attenuated sympathetic activity and hypertensive response in the paraventricular nucleus | decrease of reactive oxygen species and pro-inflammatory cytokines | (33) |
| Allicin | exert anti-hypertensive effects | Dependent on endothelium | (34) |
| Sodium thioulate | Protective in HBP | vasodilating and anti-oxidative properties | (35) |
| thiourea | vasorelaxing effects | membrane hyperpolarization, mediated by activation of KATP and Kv7 potassium channels. | (36) |

CSE, cystathionine-c-lyase; CBS, cystathionine-b-synthase; HBP, high blood pressure; AMPK, adenosine monophosphate activated protein kinase; RAS, renin-angiotensin system; NLRP3, Nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing 3; NO, nitric oxide; eNOS, endothelial nitric oxide synthase; Cx, Connexin; VEGF, vascular endothelial growth factor; KATP, ATP-sensitive potassium channel.
superoxide generation in high-fat diet ApoE(-/-) mice, and therefore impaired atherosclerotic lesion development (68).

Apart from supplementation of traditional donors, administration of organic H2S donors would also be protective in maintaining EC function against AS. GYY4137 can induce autophagy and can protect ECs from Ox-LDL-induced apoptosis by activating Sirt1 (69). AP39 and AP123, the newly synthesized mitochondria-target H2S donors, are reported to protect endothelial cells from highglycemia-induced injury via preserving mitochondria function (70). With the development of pharmacy technology, the synthesis of new H2S releasing compounds are promising against AS.

There is crosstalk between H2S and NO in regulating the pathogenesis of AS. H2S was reported to increase NO production and upregulated the expression of inducible nitric oxide synthase (iNOS) (71). ApoE(-/-) mice fed with PAG was found with enhanced atherosclerotic lesion area, and with decreased NO levels, suggesting H2S could regulate atherosclerosis progression through NO crosstalk. H2S partially restores aortic endothelium-dependent relaxation in ApoE(-/-) mice, which may be related to increased phosphorylation of eNOS in the aorta (72).

To summarize, large numbers of studies have demonstrated the protective role of H2S in anti-AS via maintaining normal EC function, however, the mechanisms need deeper understanding. As a result, this will further facilitate the development of drug therapy for treating AS.

Inflammation

AS is a chronic vascular inflammatory disease and inflammation exists at all stages of AS (73). H2S has been reported to have anti-inflammatory effects, further regulating the pathogenesis of AS. Deeper understating of the protective effects of H2S donors via inhibiting inflammation will help provide a new way for future AS treatment.

Endogenous H2S production has been reported to regulate inflammation in AS by its producing enzymes. Alterations of CSE/H2S pathway may thus be involved in atherosclerosis pathogenesis (74). However, the underlying mechanisms are poorly understood. Endogenous CSE/H2S can directly sulfhydryl SIRT1, promote its deacytlation activity, and increase SIRT1 stability, thus reducing atherosclerotic plaque formation, by reducing vascular related inflammation (75). In another study, zofenopril at, the active metabolite of zofenopril has been reported to exert anti-inflammatory activity in vascular cells through its ability to increase H2S availability, therefore providing a potential target for treating AS (76). Moreover, CSE/H2S pathway has been reported to play an anti-inflammatory role in oxidized low-density lipoprotein (ox-LDL)-stimulated macrophage by suppressing c-Jun N-terminal kinase (JNK)/NF-kB signaling pathway (74). Furthermore, high fat diet is a predisposing factor for the progression of AS. It is reported that high fat diet might cause impaired function of CSE/H2S pathway, aggravating inflammation and posing risks to the development of AS (77). Apart from CSE regulation pathway, it is shown that deletion of CBS would impair endogenous H2S production and promote inflammatory reaction in AS-susceptible mice (78). This provided evidence that H2S releasing diet may help protect against AS.

Apart from endogenous H2S in regulating AS related inflammation, exogenous H2S administration also had an important role in AS. NaHS was originally the most widely used H2S donor in studying the effects of H2S in anti-AS. Numerous studies have demonstrated NaHS to be protective against AS by reducing inflammation (74, 75, 79, 80). In addition to traditional H2S releasing salts, new synthesized H2S donors have shown great potential with physiological properties. Whiteman and et al. demonstrated that GYY4137 could significantly inhibit lipopolysaccharide (LPS) -induced release of pro-inflammatory mediators and promoted the release of the anti-inflammatory chemokines. While NaHS exerted a bidirectional effect at high concentrations. This finding can partly explain the complex regulation system of H2S in inflammation (81). GYY4137, has also been proved to be protective against the development of diabetes-accelerated AS by preventing the activation of NLPR3 inflammasome (82). Furthermore, H2S rich compounds are reported to upregulate the expression of glutathione (GSH) and glutamate-cysteine ligase catalytic (GCLC) subunit, inhibiting inflammation, and exerting beneficial effects of mitigating AS (83). The effects of endogenous H2S and exogenous H2S in AS were listed in Table 2.

H2S and angiogenesis

Angiogenesis is a process of new vessel formation from the existing vasculature (84). It is found that H2S might be a pro-angiogenic factor, promoting angiogenesis in different diseases and increase the expression of angiogenesis related biomarkers, including diabetes mellitus (DM), ischemic diseases and cancer (85).

H2S and DM related angiogenesis

DM is the leading cause of mortality worldwide, causing a variety of vascular complications (86). Impaired angiogenesis is a strong feature of DM and it can commonly induce refractory wound lesions. Therefore, promoting angiogenesis is of crucial importance for DM patients.

DM patients are reported with lower concentration of H2S in serum and in curtenous tissues, indicating the impaired synthesis of H2S production in DM patients (87, 88). Therefore, regulation of endogenous H2S production and production enzymes are a potential treatment for DM related wound healing. CSE down-
**TABLE 2** Effects of Endogenous H$_2$S and Exogenous H$_2$S in AS.

| Source | Gene/Compound | Effects | Mechanism | Reference |
|--------|---------------|---------|-----------|-----------|
| Endogenous | CSE | CSE deficiency upregulated the levels of IL-1ß and IL-18 inflammatory cytokines | Via activating TXNIP-NLRP3-IL-18/IL-1ß-NO signaling pathway | (47) |
| Endogenous | CSE | CSE depletion contributes to the development of endothelial dysfunction in AS | Via activating MAPK/TXNIP pathway | (48) |
| Exogenous | NaHS | protective against the formation of uremia accelerated atherosclerosis | Via activating eNOS/PKC ßII/Akt signaling pathway | (49) |
| Exogenous | NaHS | reducing atherosclerotic plaque formation, by reducing vascular related inflammation | sulfhydryl SIRT1, promote its deacetylation activity, and increase SIRT1 stability | (50) |
| Exogenous | NaHS | anti-inflammatory role in ox-LDL-stimulated macrophage | suppressing JNK/NF-kB signaling pathway | (51) |
| Exogenous | GYY4137 | reducing oxidant-provoked vascular endothelial dysfunction | upregulating ACE2 expression | (52) |
| Exogenous | GYY4137 | protect endothelial cells from Ox-LDL-induced apoptosis by activating Sirt1 | induce autophagy | (53) |
| Exogenous | GYY4137 | inhibit lipopolysaccharide -induced release of pro-inflammatory mediators and promoted the release of the anti-inflammatory chemokines | Not applicable | (54) |
| Exogenous | GYY4137 | be protective against the development of diabetes-accelerated AS | preventing the activation of NLPR3 inflammasome | (55) |
| Exogenous | AP39 and API23 | protect endothelial cells from highlyglycemia-induced injury | preserving mitochondria function | (56) |
| Exogenous | zofenopril | exert anti-inflammatory activity in vascular cells | In a CSE/H$_2$S-mediated manner | (57) |

CSE, cystathionine-c-lyase; NO, nitric oxide; TXNIP, thioredoxin-interacting protein; NLRP3, Nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing 3; NO, nitric oxide; MAPK, mitogen-activated protein kinase; eNOS, endothelial nitric oxide synthase; PKC, protein kinase C; SIRT, Sirtuin; ox-LDL, oxidized low-density lipoprotein; JNK, c-Jun N-terminal kinase; ACE2, angiotensin converting enzyme 2; ER, endoplasmic reticulum; HUVEC, human umbilical vein endothelial cell.

**Regulation is reported to play a role in the pathogenesis of diabetic impaired wound healing** (89). Danhong, a traditional Chinese herb medicine, has been reported to promote angiogenesis in the diabetic hind limb ischemia model through activation of local CSE-H$_2$S-vascular endothelial growth factor (VEGF) axis (90). Furthermore, DM leads to the dysfunction of 3-MST/H$_2$S and 3-MST might be a therapeutic target for DM patients (91). Besides, 3-MST/H$_2$S axis was also reported to exert pro-angiogenic effects via modulating mitochondrial respiration and increasing mitochondrial adenine triphosphate (ATP) production (92).

Numerous studies have proved H$_2$S to be a pro-angiogenic factor (89, 93, 94). For example, H$_2$S has been reported to increase angiogenesis in injured ischemic adductor muscle and to promote the ischemic diabetic wound healing in type 2 diabetic db/db mice (95). H$_2$S improves wound healing by restoration of endothelial progenitor cell (EPC) functions and activation of Ang-1 in type 2 diabetic mice (96). H$_2$S can also improve diabetic impaired wound healing by attenuating inflammation and increasing angiogenesis (97). These findings together imply that H$_2$S played a role in DM mediated angiogenesis.

Apart from traditional widely-know H$_2$S releasing donors, new and effective donors containing H$_2$S moiety have been synthesized and utilized in DM related diseases. HA-JK1 and SA/JK-1 have been synthesized as examples. For HA-JK1, an *in situ* forming biomimetic hyaluronic acid (HA) hydrogel was used as a matrix to dope a pH-controllable H$_2$S donor, JK1, to form a novel HA-JK1 hybrid system. This HA-JK1 hydrogel was designed as an ideal delivery scaffold for JK1 with pH-dependent prolonged H$_2$S releasing profile (97). For SA/JK-1, which was capable of releasing H$_2$S consistently under acidic pH conditions by absorbing exudate at the wound interface. The SA/JK-1 sponge exhibited biocompatibility to fibroblasts and promoted cell migration *in vitro*, and exhibited obviously positive influence on wound healing, therefore providing an effective treatment for non-healing wound (98). Interestingly, microparticles containing NaHS, have been synthesized using the emulsion technique, called NaHS@MPs. It can sustainably release H$_2$S under physiological conditions by absorbing exudate at the wound interface. The SA/JK-1 sponge exhibited biocompatibility to fibroblasts and promoted cell migration *in vitro*, and exhibited obviously positive influence on wound healing, therefore providing an effective treatment for non-healing wound (98). Interestingly, microparticles containing NaHS, have been synthesized using the emulsion technique, called NaHS@MPs. It can sustainably release H$_2$S under physiological conditions by absorbing exudate at the wound interface. The SA/JK-1 sponge exhibited biocompatibility to fibroblasts and promoted cell migration *in vitro*, and exhibited obviously positive influence on wound healing, therefore providing an effective treatment for non-healing wound (98). Interestingly, microparticles containing NaHS, have been synthesized using the emulsion technique, called NaHS@MPs. It can sustainably release H$_2$S under physiological conditions by absorbing exudate at the wound interface.

Collectively, the role of H$_2$S in DM related angiogenesis is gaining increasingly attention. However, there remains large space to be explored to clinical practice.

**H$_2$S and angiogenesis in ischemic diseases**

Ischemic diseases are accompanied by shortage of blood supply. Angiogenesis would potentially increase the blood flow, therefore exerting the treating effects.
Modulation of endogenous H₂S generation has a role in angiogenesis. CBS, CSE and 3-MST responded differently to angiogenesis. CSE is reported to promote VEGF-dependent angiogenesis through H₂S generation under amino acid restriction (100). However, in another study, Tao and et al. found that CBS could promote vascular endothelial cell migration both under normoxic and minor hypoxia conditions (10% oxygen), while CSE had the opposite effects. 3-MST can accelerate the migration of endothelial cells in hypoxia, while no such effect was observed under normoxic conditions. They further found that 3-MST can modulate the endothelial cell migration, rather than CSE or CBS. Their study highlighted the need to get deeper understanding of the different functions of the H₂S producing enzymes under different conditions (101). Furthermore, thiosulfate, one of the products formed during oxidative H₂S metabolism, has surprisingly demonstrated inhibitory effects on VEGF-dependent endothelial cell proliferation, combined with reduction of CSE expression level (102). Therefore, the role of endogenous H₂S on angiogenesis is controversial and requires more study to elucidate the potential mechanisms.

GYY4137 was reported to promote HHcy-mediated neangiogenesis impairment in the ischemic hind limbs of post femoral artery ligation model via peroxisome proliferator-activated receptor (PPAR)-γ/VEGF axis (103). DATS, an organic polysulﬁde releasing H₂S, has been demonstrated to promote angiogenesis in hindlimb ischemia via Akt-eNOS signaling pathway (104). Furthermore, NaHS could increase NO bioavailability and promote angiogenesis in ischemia hindlimb (105). NaHS exert proangiogenic effect mediated by interaction between the upregulated VEGF in the skeletal muscle cells and the VEGF receptor 2 (106). In another report, NaHS exerts proangiogenic effects through dependent on activation of Akt (107).

Recently, with the development of material synthesis technology, various H₂S releasing compounds have been synthesized to enhance H₂S releasing properties. For instance, A poly (D, L-lactic-co-glycolic acid) microparticle system that contains DATS, called DATS@MPs, possess the property of slow and long-term H₂S release. DATS@MPs have been reported to promote therapeutic angiogenesis in an ischemic mouse limb model through activating nuclear respiratory factor 2 (Nrf2) translocation, thus providing therapeutic potential in treating ischemic diseases (108). Moreover, ZYZ-803, a novel synthetic H₂S-NO hybrid molecule, which can slowly release H₂S and NO, has been reported to exert pro-angiogenic effects via SIRT1 dependent pathway. The pro-angiogenic effects of H₂S are also dependent on CSE and eNOS expression via cross-talk between signal transduction and activator of transcription 3 (STAT3) and Ca²⁺/CaM-dependent protein kinase II (CaMKII) activation (109, 110).

Apart from ischemic limb diseases, myocardial infarction (MI) is another serious ischemic disease, which poses great danger to people’s health. GYY4137 was reported to exert proangiogenic effects following MI via endogenous natriuretic peptide activation (111). Diallyl trisulfide, a long-lasting H₂S donor, can mitigate left ventricular dysfunction via inducing angiogenesis in over-loaded heart failure (112). NaHS was reported to increase angiogenesis and improve left ventricular function after MI (113). Besides, NaHS was also reported to promote angiogenesis, and mitigating the progression of heart failure by inducing matrix metalloproteinase (MMP)-2 activation and inhibiting MMP-9 and tissue inhibitor of matrix metalloproteinase (TIMP)-3 expression (114).

Newly and novel H₂S releasing compounds have been synthesized, with the aim to over the limitations of traditional H₂S releasing donors. Liang and et al. developed a macromolecular H₂S prodrug. The compound comprised of a 2-aminopyridine-5-thiocarboxamide (a small-molecule H₂S donor) on partially oxidized alginate (ALG-CHO), to obtain the slow and continuous release of endogenous H₂S. They further formed a stem cell-loaded conductive H₂S-releasing hydrogel through the Schiff base reaction between ALG-CHO and gelatin. They utilized the hydrogel in treating MI, demonstrating a dramatical improvement of the cardiac functions in rats (115). Moreover, S-Propargyl-Cysteine (SPRC), a novel water-soluble modulator of endogenous H₂S production, has been demonstrated to exhibit pro-angiogenic effects via the activation of STAT3. SPRC therefore provides a novel therapeutic strategy for ischemia heart diseases (116).

H₂S and NO shared interactions in regulating angiogenesis. Aortic rings harvested from eNOS−/− mice exhibited no microvessel outgrowth in response to NaHS, compared with wild-type controls, demonstrating that NO was essential for the pro-angiogenic effect of H₂S. Besides, chemical inhibition of CSE attenuated NO-mediated cGMP angiogenesis (44). Apart from this, NO donors increased CSE dependent H₂S biogenesis in a cGMP-dependent manner. Pre-treating NO donors increased CSE mRNA and protein levels in smooth muscle cells increased H₂S production (117). Taken together, NO and H₂S contributed mutually in regulating angiogenesis.

In summary, H₂S plays an important role in different vascular diseases. The structure of normal artery consisted of 3 layers. The inner layer lined by a monolayer of ECs is closely contacted with blood; the middle layer composed of VSMCs is located at the complex extracellular matrix; and the outer layer of arteries is composed of mast cells, nerve endings, and microvessels. Imbalance and dysfunction of the 3 layers lead to the pathogenesis of vascular diseases, especially dysfunction of EC and SMC (7). This indicates the universal functions of H₂S in regulating different vascular diseases. Studies have focused on the effects of H₂S from endogenous H₂S production and exogenous H₂S administration. However, the application of H₂S in vascular diseases is still in the basic research stage. Studies and experiments of H₂S in treating vascular diseases are required.

Future research should focus on the role and mechanism of H₂S and different H₂S releasing donors in treating vascular diseases. Synthetic H₂S donors have been developed to
overcome the disadvantages of traditional H₂S donors. They can be categorized by their class of triggering mechanisms, possessing specific delivery system and H₂S releasing properties (118). Continuous improvements in the interaction and crosstalk between different gas transmitters in the control of vascular diseases. Exploring the therapeutic potential in regulating vascular diseases will be promising in the near future.

Author contributions

CZ and QL wrote the first draft. XL, RW, TG, XZ and BL provided the organization and framework of the article. KL and RC provided critical revisions. All authors contributed to the article and approved the submitted version.

Funding

The study was supported by Natural Science Foundation of China (82000390), China Postdoctoral Science Foundation (2020M681048), and Special Fund of Jilin Province (2020SCZT038). Jilin Provincial Finance Department, China (2020SCZT091). The Jilin Science and Technology Agency funds in China, China (20210402003GH).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Li L, Rose P, Moore PK. Hydrogen sulfide and cell signaling. Annu Rev Pharmacol Toxicol (2011) 51:169–87. doi: 10.1146/annurev-pharmtox-010510-100505

2. Mustafa AK, Gadalla MM, Sen N, Kim S, Mu W, Gazi SK, et al. H2S signals through protein S-sulfhydration. Sci Signal (2009) 2:ra72. doi: 10.1126/scisignal.2009464

3. Wallace JL, Wang R. Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter. Nat Rev Drug Discov (2015) 14:329–45. doi: 10.1038/nrd4433

4. Lv B, Chen S, Tang C, Jin H, Du J and Huang Y. Hydrogen sulfide and vascular regulation - an update. J Adv Res (2021) 27:85–97. doi: 10.1016/j.jare.2020.05.007

5. Yuan S, Kevil CG. Nitric oxide and hydrogen sulfide regulation of ischemic vascular remodeling. Microcirculation (2016) 23:134–45. doi: 10.1111/mirc.12248

6. Yang G, Wang R. H2S and blood vessels: An overview. Handb Exp Pharmacol (2015) 230:85–110. doi: 10.1007/978-3-319-18144-8_4

7. Kanagy NL. Szabo c and papapetropoulos a. vascular biology of hydrogen sulfide. Am J Physiol Cell Physiol (2017) 312:C537–49. doi: 10.1152/ajpcell.00329.2016

8. Tian X, Zhou D, Zhang Y, Song Y, Zhang Q, Bu D, et al. Persulfidation of transcription factor FOXO1 at cysteine 457: A novel mechanism by which H2S inhibits vascular smooth muscle cell proliferation. J Adv Res (2021) 27:155–64. doi: 10.1016/j.jare.2020.08.023

9. Dong N, Piao H, Li B, Xu J, Wei S, Liu K. Poor management of hypertension is an important precipitating factor for the development of acute aortic dissection. J Clin Hypertens (Greenswich) (2019) 21:804–12. doi: 10.1111/jch.13556

10. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). J Hypertens (2013) 31:1281–357. doi: 10.1097/HJH.0b013e32836296cc

11. Kurz JL, Graney JL, Santhanam L, Alexander LM. Evidence for a functional vasodilatory role for hydrogen sulphide in the human cutaneous microvasculature. J Physiol (2015) 595:2121–9. doi: 10.1111/jpf.2015054

12. Sun NL, Xi Y, Yang SN, Ma Z, Tang GS. Plasma hydrogen sulfide and homocysteine levels in hypertensive patients with different blood pressure levels and complications. Zhonghua Xin Xue Guan Bing Za Zhi (2007) 35:1145–8.

13. Shi MM, Wang JI, Zhang LQ, Qin M, Huang YW. Association between hydrogen sulfide and ONA-associated hypertension: a clinical study. Sleep Breath (2020) 24:745–50. doi: 10.1007/s11325-019-01997-y

14. Possemato-Vieira JS, Goncalves-Rizzii VV, do Nascimento RA, Wandekin RR, Caldeira-Dias M, Chiminis J, et al. Clinical and experimental evidences of hydrogen sulfide involvement in lead-induced hypertension. BioMed Res Int (2018) 2018:4627391. doi: 10.1155/2018/4627391

15. Aminzadeh MA, Vaziri ND. Downregulation of the renal and hepatic hydrogen sulfide (H2S)-producing enzymes and capacity in chronic kidney disease. Nephrol Dial Transplant (2012) 27:498–504. doi: 10.1093/ndt/gfr560

16. Peleli M, Bili S, Li Z, Chatzianastasiou A, Varela A, Katsouda A, et al. Cardiovascular phenotype of mice lacking 3-mercaptopropionate sulfurtransferase. Biochem Pharmacol (2020) 176:113833. doi: 10.1016/j.bcp.2020.113833

17. Cui C, Fan J, Zeng Q, Cai J, Yin Y, Chen Z, et al. CD4(+)- T-cell endogenous cystathionine gamma-lyase-hydrogen sulfide attenuates hypertension by sulfhydrating liver kinase B1 to promote T regulatory cell differentiation and proliferation. Circulation (2020) 142:1752–69. doi: 10.1161/CIRCULATIONAHA.119.045344

18. Han D, Ju H, Tang C. The possible role of hydrogen sulfide on the pathogenesis of spontaneous hypertension in rats. Biochem Biophys Res Commun (2004) 313:12–7. doi: 10.1016/j.bbrc.2003.11.081

19. Roy A, Khan AH, Islam MT, Prieto MC, Majid DS. Interdependency of cystathionine gamma-lyase and cystathione beta-synthase in hydrogen sulfide-induced blood pressure regulation in rats. Am J Hypertens (2012) 25:74–81. doi: 10.1016/j.ajh.2011.149

20. Li L, Hsu A, Moore PK. Actions and interactions of nitric oxide, carbon monoxide and hydrogen sulfide in the cardiovascular system and in inflammation-a tale of three gases! Pharmaco Ther (2009) 123:386–400. doi: 10.1016/j.pharmthera.2009.05.005

21. Ali MY, Ping CY, Mok YY, Ling L, Whiteman M, Bhatia M, et al. Regulation of vascular nitric oxide in vitro and in vivo: a new role for endogenous hydrogen sulfide? Br J Pharmacol (2006) 149:625–34. doi: 10.1038/sj.bjp.0706906

22. Szejarto IA, Marko L, Filipovic MR, Miljovic J, Tabeling C, Tsvetkov D, et al. Cystathionine gamma-lyase-Produced hydrogen sulfide controls endothelial NO bioavailability and blood pressure. Hypertension (2018) 71:1216–7. doi: 10.1161/HYPERTENSIONAHA.117.10562

23. Zhao W, Ndisang JF, Wang R. Modulation of endogenous production of H2S in rat tissues. Can J Physiol Pharmacol (2003) 81:848–53. doi: 10.1139/y03-077
44. Coletta C, Papapetropoulos A, Erdelyi K, Olah G, Modis K, Panopoulos P, et al. Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angio genesis and endothelium-dependent vasorelaxation. Proc Natl Acad Sci U S A (2012) 109:9161–6. doi: 10.1073/pnas.1209216109

45. Kiss L, Deitch EA, Szabo C. Hydrogen sulfide decreases adenosine triphosphate levels in aortic rings and leads to vasorelaxation via metabolic inhibition. Life Sci (2008) 83:589–94. doi: 10.1016/j.lfs.2008.08.006

46. Hedegaard ER, Goularte A, Winther AK, Arcanjo DD, Aalting M, Renaltau NS, et al. Involvement of potassium channels and calcium-independent mechanisms in hydrogen sulfide-induced relaxation of rat mesenteric small arteries. J Pharmacol Exp Ther (2016) 356:53–63. doi: 10.1124/jpet.115.272077

47. Szabo C, Ranzy A, Modis K, Andriamihaja M, Murghes R, Coletta C, et al. Regulation of mitochondrial bioenergetic function by hydrogen sulfide. part i. biochemical and physiological mechanisms. Br J Pharmacol (2014) 171:2099–122. doi: 10.1111/bph.12906

48. Nair A. Pharmacologic therapy for pulmonary artery hypertension. Curr Opin Cardiol (2020) 35:643–56. doi: 10.1097/HCO.0000000000000796

49. Ariyaratnam P, Loubani M, Morice AH. Hydrogen sulfide vasodilates human pulmonary arteries: a possible role in pulmonary hypertension? Microvasc Res (2013) 90:135–7. doi: 10.1016/j.mvr.2013.09.002

50. Castro-Pérez I, Perez-Zaghib F. Hydrogen sulfide inhibits Ca2+ release through InsP3 receptors and releases airway smooth muscle. J Physiol (2013) 591:599–605. doi: 10.1113/jphysiol.2013.257790

51. Wu J, Pan W, Wang C, Dong H, Xing L, Hou J, et al. H2S attenuates endoplasmic reticulum stress in hypertension-induced pulmonary artery hypertension. Biosci Rep (2019) 39:1-13. doi: 10.1042/BSR20190384

52. Rashid S, Heer JK, Garle MJ, Alexander SP, Roberts RE. Hydrogen sulphide–induced relaxation of porcine peripheral bronchioles. Br J Pharmacol (2016) 188:1902–10. doi: 10.1111/bph.14084

53. Xiao H, Zhang CY, Jin J, Tang CJ, Du JB. Hydrogen sulfide regulates lung tissue-oxidized glutathione and total antioxidant capacity in hypoxic pulmonary hypertensive rats. Acta Pharmacol Sin (2008) 29:670–9. doi: 10.1111/j.1745-7524.2008.00796.x

54. Liao L, Liu D, Tang C, Du J, Liu AD, Holmberg L, et al. Sulfur dioxide upregulates the inhibited endogenous hydrogen sulfide pathway in rats with pulmonary hypertension induced by high blood blood flow. Biochim Biophys Acta (2013) 433:519–25. doi: 10.1016/j.bbadis.2013.03.014

55. Taleb S. Inflammation in arteriosclerosis. Arch Cardiovasc Dis (2016) 109:708–15. doi: 10.1016/j.acvd.2016.04.002

56. Liu Q, Zhang H, Lin J, Zhang R, Chen S, Liu W, et al. Clq/TNF-related protein 9 inhibits the cholesterol-induced vascular smooth muscle cell phenotype switch and cell dysfunction by activating AMP-dependent kinase. J Cell Mol Med (2017) 21:2823–36. doi: 10.1111/jcmm.13196

57. Wang ZL, Wu J, Guo W, Zhu YZ. Atherosclerosis and the hydrogen sulfide signaling pathway - therapeutical approaches to disease prevention. Cell Physiol Biochem (2017) 42:859–75. doi: 10.1007/s00841-017-2466-1

58. Lee DY, Chiou JJ. Atherosclerosis and flow: roles of epigenetic modulation in vascular endothelium. J Biomol Sci (2019) 28:56. doi: 10.1186/s12882-019-0551-6

59. Theodorou K, Boon RA. Endothelial cell metabolism in arteriosclerosis. Front Cell Dev Biol (2018) 6:82. doi: 10.3389/fcell.2018.00082

60. Mani S, Liu H, Unterreiner A, Wu L, Yang G, Austin RC, et al. Decreased endogenous production of hydrogen sulfide accelerates atherosclerosis. Circulation (2018) 137:2523–34. doi: 10.1161/CIRCULATIONAHA.118.035439

61. Yue LM, Gao YM, Han RH. Evaluation on the effect of hydrogen sulfide on the NLRP3 signaling pathway and its involvement in the pathogenesis of atherosclerosis. J Cell Biochem (2019) 120:481-92. doi: 10.1002/jcb.27404

62. Tian D, Dong J, Jin S, Teng X, Wu Y. Endogenous hydrogen sulfide–mediated MAPK inhibition preserves endothelial function through TXNIP signaling. Free Radic Biol Med (2017) 110:291–9. doi: 10.1016/j.freeradbiol.2017.06.016

63. Xiong R, Lu ZG, Song J, Li H, Wang S. Molecular mechanisms of hydrogen sulfide against uricemic accelerated atherosclerosis through cPKCbetaII/Akt signal pathway. BMJ. Neprol (2019) 20:3358. doi: 10.11282/19159-1554-4

64. Rao G, Murphy B, Dey A, Dwivedi SKD, Zhang Y, Roy RV, et al. Cystathionine beta synthase regulates mitochondrial dynamics and function in endothelial cells. FASEB J (2020) 34:9572–92. doi: 10.1096/fasebj.202001173R

65. Lin Y, Zeng H, Guo L, Gu T, Wang C, Zhang H. Hydrogen sulfide attenuates atherosclerosis in a partially ligated carotid artery mouse model via regulating angiotensin converting enzyme 2 expression. Front Physiol (2017) 8:782. doi: 10.3389/fphys.2017.00782

66. Hu HJ, Jiang ZS, Jiu ZH, Shi JH, Liu QM. Protective effects of hydrogen sulfide against angiotensin II-induced endoplasmic reticulum stress in HUVECs. Mol Med Rep (2017) 15:2213–22. doi: 10.3892/mmr.2017.6238

Zhu et al. 10.3389/fendo.2022.934231
feeding a high fat diet on hydrogen sul
Pharmacol Res
10.1089/ars.2017.7195
Hyperhomocysteinemia potentiates diabetes-impaired EDHF-induced vascular
caused vascular in
Frontiers inEndocrinology frontiersin.org10
hydrogen sul
mammalian cardiovascular system.
met.2014.0022
85. Terzuoli E, Monti M, Vellecco V, Bucci M, Cirino G, Ziche M, et al. The novel mitochondria-targeted hydrogen sul
doctoral dissertation
intervention for treatment of peripheral arterial disease.
110. Xiong Y, Chang LL, Tran R, Dai T, Zhong R, Mao YC, et al. ZYZ-803, a novel hydrogen sulfide-nitric oxide conjugated donor, promotes angiogenesis via cross-talk between STAT3 and CaMKII. *Acta Pharmacol Sin* (2020) 41:218–28. doi: 10.1038/s41401-019-0255-3

111. Lilyanna S, Peh MT, Liew OW, Wang P, Moore PK, Richards AM, et al. GYY4137 attenuates remodeling, preserves cardiac function and modulates the natriuretic peptide response to ischemia. *J Mol Cell Cardiol* (2015) 87:27–37. doi: 10.1016/j.yjmcc.2015.07.028

112. Polhemus D, Kondo K, Bhushan S, Bir SC, Kevil CG, Murohara T, et al. Hydrogen sulfide attenuates cardiac dysfunction after heart failure via induction of angiogenesis. *Circ Heart Fail* (2013) 6:1077–86. doi: 10.1161/CIRCHEARTFAILURE.113.00299

113. Qipshidze N, Metreveli N, Mishra PK, Lominadze D, Tyagi SC. Hydrogen sulfide mitigates cardiac remodeling during myocardial infarction via improvement of angiogenesis. *Int J Biol Sci* (2012) 8:430–41. doi: 10.7150/ijbs.3632

114. Givvimani S, Munjal C, Gargoum R, Sen U, Tyagi N, Vacek JC, et al. Hydrogen sulfide mitigates transition from compensatory hypertrophy to heart failure. *J Appl Physiol (1985)* (2011) 110:1093–100. doi: 10.1152/japplphysiol.01064.2010

115. Liang W, Chen J, Li L, Li M, Wei X, Tan R, et al. Conductive hydrogen sulfide-releasing hydrogel encapsulating ADSCs for myocardial infarction treatment. *ACS Appl Mater Interfaces* (2019) 11:14619–29. doi: 10.1021/acsami.9b01886

116. Kan J, Guo W, Huang C, Bao G, Zhu Y, Zhu YZ. S-propargyl-cysteine, a novel water-soluble modulator of endogenous hydrogen sulfide, promotes angiogenesis through activation of signal transducer and activator of transcription 3. *Antioxid Redox Signal* (2014) 20:2303–16. doi: 10.1089/ars.2013.5449

117. Cheng Y, Ndisang JF, Tang G, Cao K, Wang R. Hydrogen sulfide-induced relaxation of resistance mesenteric artery beds of rats. *Am J Physiol Heart Circ Physiol* (2004) 287:H2316–23. doi: 10.1152/ajpheart.00331.2004

118. Powell CR, Dillon KM, Matson JB. A review of hydrogen sulfide (H2S) donors: Chemistry and potential therapeutic applications. *Biochem Pharmacol* (2018) 149:110–23. doi: 10.1016/j.bcp.2017.11.014